Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ming-Chin Yu

Showing results (101-110 of 114) with videos related to

Pageof 12
Sort By:
International Journal of Surgery (London, England)|July 3, 2024
Do low skeletal muscle bulk and disturbed body fat mass impact tumor recurrence in stage I/II hepatocellular carcinoma undergoing surgery? An observational cohort studyChao-Wei Lee, Hsin-I Tsai, Hsiao-Mei Hsu, et al.
Hepatology (Baltimore, Md.)|November 25, 2017
Actin cytoskeleton remodeling drives epithelial-mesenchymal transition for hepatoma invasion and metastasis in miceJei-Ming Peng, Rabindranath Bera, Chih-Yung Chiou, et al.
Journal of Personalized Medicine|December 24, 2021
The Impact of Multidisciplinary Team Approach on Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal CarcinomatosisHao-Chien Hung, Po-Jung Hsu, Ting-Chang Chang, et al.
Journal of Cancer Research and Clinical Oncology|July 20, 2024
Does autoimmune disease impair the survival of hepatocellular carcinoma patients undergoing liver resection? A multi-institutional observational studyChao-Wei Lee, Hsing-Yu Chen, Ping-Han Tsai, et al.
Cancers|February 15, 2022
Rare Occurrence of Aristolochic Acid Mutational Signatures in Oro-Gastrointestinal Tract CancersAbner Herbert Lim, Jason Yongsheng Chan, Ming-Chin Yu, et al.
Biomedical Journal|April 17, 2019
Impact of age on pathological complete response and locoregional recurrence in locally advanced breast cancer after neoadjuvant chemotherapyHsu-Huan Chou, Wen-Ling Kuo, Chi-Chang Yu, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|March 24, 2025
Identification and Biological Evaluation of a Novel CLK4 Inhibitor Targeting Alternative Splicing in Pancreatic Cancer Using Structure-Based Virtual ScreeningChun-Lin Yang, Yi-Wen Wu, Huang-Ju Tu, et al.
Science Translational Medicine|October 20, 2017
Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout AsiaAlvin W T Ng, Song Ling Poon, Mi Ni Huang, et al.
Journal of Hepatology|March 24, 2009
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosageChun-Jen Liu, Po-Huang Lee, Deng-Yn Lin, et al.
World Journal of Gastroenterology|August 30, 2014
Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrenceChun-Jen Liu, Juliana Chang, Po-Huang Lee, et al.
Pageof 12

Showing results (101-110 of 114) with videos related to

Sort By:
Pageof 12
International Journal of Surgery (London, England)|July 3, 2024
Do low skeletal muscle bulk and disturbed body fat mass impact tumor recurrence in stage I/II hepatocellular carcinoma undergoing surgery? An observational cohort studyChao-Wei Lee, Hsin-I Tsai, Hsiao-Mei Hsu, et al.
Hepatology (Baltimore, Md.)|November 25, 2017
Actin cytoskeleton remodeling drives epithelial-mesenchymal transition for hepatoma invasion and metastasis in miceJei-Ming Peng, Rabindranath Bera, Chih-Yung Chiou, et al.
Journal of Personalized Medicine|December 24, 2021
The Impact of Multidisciplinary Team Approach on Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal CarcinomatosisHao-Chien Hung, Po-Jung Hsu, Ting-Chang Chang, et al.
Journal of Cancer Research and Clinical Oncology|July 20, 2024
Does autoimmune disease impair the survival of hepatocellular carcinoma patients undergoing liver resection? A multi-institutional observational studyChao-Wei Lee, Hsing-Yu Chen, Ping-Han Tsai, et al.
Cancers|February 15, 2022
Rare Occurrence of Aristolochic Acid Mutational Signatures in Oro-Gastrointestinal Tract CancersAbner Herbert Lim, Jason Yongsheng Chan, Ming-Chin Yu, et al.
Biomedical Journal|April 17, 2019
Impact of age on pathological complete response and locoregional recurrence in locally advanced breast cancer after neoadjuvant chemotherapyHsu-Huan Chou, Wen-Ling Kuo, Chi-Chang Yu, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|March 24, 2025
Identification and Biological Evaluation of a Novel CLK4 Inhibitor Targeting Alternative Splicing in Pancreatic Cancer Using Structure-Based Virtual ScreeningChun-Lin Yang, Yi-Wen Wu, Huang-Ju Tu, et al.
Science Translational Medicine|October 20, 2017
Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout AsiaAlvin W T Ng, Song Ling Poon, Mi Ni Huang, et al.
Journal of Hepatology|March 24, 2009
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosageChun-Jen Liu, Po-Huang Lee, Deng-Yn Lin, et al.
World Journal of Gastroenterology|August 30, 2014
Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrenceChun-Jen Liu, Juliana Chang, Po-Huang Lee, et al.
Pageof 12